The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors
Open accessAbstract
Immune checkpoint inhibitors (ICIs) have been changing the paradigm of cancer treatment. However, immune-related adverse effects (irAEs) have also increased with the exponential increase in the use of ICIs. ICIs can break up the immunologic homeostasis and reduce T-cell tolerance. Therefore, inhibition of immune checkpoint can lead to the activation of autoreactive T-cells, resulting in various irAEs similar to autoimmune diseases. Gastrointestinal toxicity, endocrine toxicity, and dermatologic toxicity are common side effects. Neurotoxicity, cardiotoxicity, and pulmonary toxicity are relatively rare but can be fatal. ICI-related gastrointestinal toxicity, dermatologic toxicity, and hypophysitis are more common with anti- CTLA-4 agents. ICI-related pulmonary toxicity, thyroid dysfunction, and myasthenia gravis are more common with PD-1/PD-L1 inhibitors. Treatment with systemic steroids is the principal strategy against irAEs. The use of immune-modulatory agents should be considered in case of no response to the steroid therapy. Treatment under the supervision of multidisciplinary specialists is also essential, because the symptoms and treatments of irAEs could involve many organs. Thus, this review focuses on the mechanism, clinical presentation, incidence, and treatment of various irAEs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357 · cited 2×
“The incidence of irAEs is higher in ICI combination therapy than in ICI monotherapy (4).”
BackgroundImmune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
Mahmood, S. S., Fradley, M. G., Cohen, J. V., Nohria, A., Reynolds, K. L., Heinzerling, L. M., Sullivan, R. J., Damrongwatanasuk, R., Chen, C. L., Gupta, D., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.037 · Cited by 1,608
Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,572
Schachter, J., Ribas, A., Long, G. V., Arance, A., Grob, J.-J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31601-x · Cited by 1,225
Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
Naidoo, J., Wang, X., Woo, K. M., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J. E., Segal, N. H., Callahan, M. K., Lesokhin, A. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.2005 · Cited by 1,215
Barroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., & Tolaney, S. M. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3064 · Cited by 1,115
Shaverdian, N., Lisberg, A. E., Bornazyan, K., Veruttipong, D., Goldman, J. W., Formenti, S. C., Garon, E. B., & Lee, P. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30380-7 · Cited by 1,091
Horvat, T. Z., Adel, N. G., Dang, T.-O., Momtaz, P., Postow, M. A., Callahan, M. K., Carvajal, R. D., Dickson, M. A., D'Angelo, S. P., Woo, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8448 · Cited by 1,064
Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., et al. (2016) · Nature Communications · doi:10.1038/ncomms10391 · Cited by 987
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30533-6 · Cited by 942
Microbiota: a key orchestrator of cancer therapy
Roy, S., & Trinchieri, G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.13 · Cited by 883
Freeman-Keller, M., Kim, Y., Cronin, H., Richards, A., Gibney, G., & Weber, J. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1136 · Cited by 863 · cited 1×
“Among the various symptoms of dermatologic toxicity, rash and vitiligo are suspected to be preferable marker for ICI treatment response (8,82).”
BackgroundFecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Wang, Y., Wiesnoski, D. H., Helmink, B. A., Gopalakrishnan, V., Choi, K., DuPont, H. L., Jiang, Z.-D., Abu-Sbeih, H., Sanchez, C. A., Chang, C.-C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0238-9 · Cited by 740 · cited 1×
“Some cases of fecal microbiota transplantation have been reported in patients who did not respond to systemic steroids or in iximab (28).”
BackgroundIwama, S., De Remigis, A., Callahan, M. K., Slovin, S. F., Wolchok, J. D., & Caturegli, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008002 · Cited by 715
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
Cortazar, F. B., Marrone, K. A., Troxell, M. L., Ralto, K. M., Hoenig, M. P., Brahmer, J. R., Le, D. T., Lipson, E. J., Glezerman, I. G., Wolchok, J., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.04.008 · Cited by 650
Teulings, H.-E., Limpens, J., Jansen, S. N., Zwinderman, A. H., Reitsma, J. B., Spuls, P. I., & Luiten, R. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4756 · Cited by 625
Baxi, S., Yang, A., Gennarelli, R. L., Khan, N., Wang, Z., Boyce, L., & Korenstein, D. (2018) · BMJ · doi:10.1136/bmj.k793 · Cited by 578
Immune checkpoint inhibitors and cardiovascular toxicity
Lyon, A. R., Yousaf, N., Battisti, N. M. L., Moslehi, J., & Larkin, J. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30457-1 · Cited by 575
Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
Cuzzubbo, S., Javeri, F., Tissier, M., Roumi, A., Barlog, C., Doridam, J., Lebbe, C., Belin, C., Ursu, R., & Carpentier, A. F. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.001 · Cited by 571
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Chang, L.-S., Barroso-Sousa, R., Tolaney, S. M., Hodi, F. S., Kaiser, U. B., & Min, L. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00006 · Cited by 532
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
De Martin, E., Michot, J.-M., Papouin, B., Champiat, S., Mateus, C., Lambotte, O., Roche, B., Antonini, T. M., Coilly, A., Laghouati, S., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.01.033 · Cited by 520
Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor–Related Cardiotoxicity
Escudier, M., Cautela, J., Malissen, N., Ancedy, Y., Orabona, M., Pinto, J., Monestier, S., Grob, J.-J., Scemama, U., Jacquier, A., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.030571 · Cited by 517
Nishino, M., Ramaiya, N. H., Awad, M. M., Sholl, L. M., Maattala, J. A., Taibi, M., Hatabu, H., Ott, P. A., Armand, P. F., & Hodi, F. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1320 · Cited by 499
Faje, A. T., Sullivan, R., Lawrence, D., Tritos, N. A., Fadden, R., Klibanski, A., & Nachtigall, L. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2306 · Cited by 479
Voskens, C. J., Goldinger, S. M., Loquai, C., Robert, C., Kaehler, K. C., Berking, C., Bergmann, T., Bockmeyer, C. L., Eigentler, T., Fluck, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053745 · Cited by 468
Bonaca, M. P., Olenchock, B. A., Salem, J.-E., Wiviott, S. D., Ederhy, S., Cohen, A., Stewart, G. C., Choueiri, T. K., Di Carli, M., Allenbach, Y., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.034497 · Cited by 458
Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis
Salem, J.-E., Allenbach, Y., Vozy, A., Brechot, N., Johnson, D. B., Moslehi, J. J., & Kerneis, M. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1901677 · Cited by 443
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy162 · Cited by 431
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
Belum, V. R., Benhuri, B., Postow, M. A., Hellmann, M. D., Lesokhin, A. M., Segal, N. H., Motzer, R. J., Wu, S., Busam, K. J., Wolchok, J. D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.010 · Cited by 418
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Delaunay, M., Cadranel, J., Lusque, A., Meyer, N., Gounant, V., Moro-Sibilot, D., Michot, J.-M., Raimbourg, J., Girard, N., Guisier, F., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00050-2017 · Cited by 412
Reardon, D. A., Gokhale, P. C., Klein, S. R., Ligon, K. L., Rodig, S. J., Ramkissoon, S. H., Jones, K. L., Conway, A. S., Liao, X., Zhou, J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0151 · Cited by 405
The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors
Tang, J., Yu, J. X., Hubbard-Lucey, V. M., Neftelinov, S. T., Hodge, J. P., & Lin, Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.210 · Cited by 382
de Filette, J., Andreescu, C., Cools, F., Bravenboer, B., & Velkeniers, B. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0843-3366 · Cited by 381
Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade
Caturegli, P., Di Dalmazi, G., Lombardi, M., Grosso, F., Larman, H. B., Larman, T., Taverna, G., Cosottini, M., & Lupi, I. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2016.08.020 · Cited by 381
Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer
Suresh, K., Naidoo, J., Lin, C. T., & Danoff, S. (2018) · Chest · doi:10.1016/j.chest.2018.08.1048 · Cited by 379
Brahmer, J. R., Lacchetti, C., & Thompson, J. A. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00005 · Cited by 377
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
Johnson, D. B., Manouchehri, A., Haugh, A. M., Quach, H. T., Balko, J. M., Lebrun-Vignes, B., Mammen, A., Moslehi, J. J., & Salem, J.-E. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0617-x · Cited by 366
Blansfield, J. A., Beck, K. E., Tran, K., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Topalian, S. L., Haworth, L. R., Levy, C., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000178913.41256.06 · Cited by 355
Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
Hughes, J., Vudattu, N., Sznol, M., Gettinger, S., Kluger, H., Lupsa, B., & Herold, K. C. (2015) · Diabetes Care · doi:10.2337/dc14-2349 · Cited by 347
Dillard, T., Yedinak, C. G., Alumkal, J., & Fleseriu, M. (2010) · Pituitary · doi:10.1007/s11102-009-0193-z · Cited by 300
Immune Checkpoint Inhibitor-Associated Myocarditis
Ganatra, S., & Neilan, T. G. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0130 · Cited by 299
Mamlouk, O., Selamet, U., Machado, S., Abdelrahim, M., Glass, W. F., Tchakarov, A., Gaber, L., Lahoti, A., Workeneh, B., Chen, S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0478-8 · Cited by 296
Sznol, M., Postow, M. A., Davies, M. J., Pavlick, A. C., Plimack, E. R., Shaheen, M., Veloski, C., & Robert, C. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.06.002 · Cited by 290
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1
Naidoo, J., Schindler, K., Querfeld, C., Busam, K., Cunningham, J., Page, D. B., Postow, M. A., Weinstein, A., Lucas, A. S., Ciccolini, K. T., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0123 · Cited by 285
Shirali, A. C., Perazella, M. A., & Gettinger, S. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.02.057 · Cited by 284
Geukes Foppen, M. H., Rozeman, E. A., van Wilpe, S., Postma, C., Snaebjornsson, P., van Thienen, J. V., van Leerdam, M. E., van den Heuvel, M., Blank, C. U., van Dieren, J., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000278 · Cited by 274
Systematic review: colitis associated with anti‐CTLA‐4 therapy
Gupta, A., De Felice, K. M., Loftus, E. V., & Khanna, S. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13281 · Cited by 273
PD-1 deficiency results in the development of fatal myocarditis in MRL mice
Wang, J., Okazaki, I.-M., Yoshida, T., Chikuma, S., Kato, Y., Nakaki, F., Hiai, H., Honjo, T., & Okazaki, T. (2010) · International Immunology · doi:10.1093/intimm/dxq026 · Cited by 270
Zen, Y., & Yeh, M. M. (2018) · Modern Pathology · doi:10.1038/s41379-018-0013-y · Cited by 266
Spain, L., Walls, G., Julve, M., O’Meara, K., Schmid, T., Kalaitzaki, E., Turajlic, S., Gore, M., Rees, J., & Larkin, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw558 · Cited by 260
Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events
González-Rodríguez, E., Rodríguez-Abreu, D., & on behalf of the Spanish Group for Cancer Immuno-Biotherapy (GETICA) (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0509 · Cited by 250
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
de Filette, J., Jansen, Y., Schreuer, M., Everaert, H., Velkeniers, B., Neyns, B., & Bravenboer, B. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2300 · Cited by 244
Tarhini, A. (2013) · Scientifica · doi:10.1155/2013/857519 · Cited by 236
Ipilimumab associated hepatitis: imaging and clinicopathologic findings
Kim, K. W., Ramaiya, N. H., Krajewski, K. M., Jagannathan, J. P., Tirumani, S. H., Srivastava, A., & Ibrahim, N. (2013) · Investigational New Drugs · doi:10.1007/s10637-013-9939-6 · Cited by 235
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
Curry, J. L., Tetzlaff, M. T., Nagarajan, P., Drucker, C., Diab, A., Hymes, S. R., Duvic, M., Hwu, W., Wargo, J. A., Torres‐Cabala, C. A., et al. (2017) · Journal of Cutaneous Pathology · doi:10.1111/cup.12858 · Cited by 232
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
Braaten, T. J., Brahmer, J. R., Forde, P. M., Le, D., Lipson, E. J., Naidoo, J., Schollenberger, M., Zheng, L., Bingham, C. O., Shah, A. A., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216109 · Cited by 230
Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy
Esfahani, K., Buhlaiga, N., Thébault, P., Lapointe, R., Johnson, N. A., & Miller, W. H. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1903064 · Cited by 224
Cutaneous adverse effects of the immune checkpoint inhibitors
Collins, L. K., Chapman, M. S., Carter, J. B., & Samie, F. H. (2017) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.12.001 · Cited by 219
Cho, J. Y., Kim, J., Lee, J. S., Kim, Y. J., Kim, S. H., Lee, Y. J., Cho, Y.-J., Yoon, H. I., Lee, J. H., Lee, C.-T., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.09.015 · Cited by 208
Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease
Totzeck, M., Schuler, M., Stuschke, M., Heusch, G., & Rassaf, T. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.01.038 · Cited by 206
Neurological toxicities associated with immune-checkpoint inhibitors
Touat, M., Talmasov, D., Ricard, D., & Psimaras, D. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000503 · Cited by 203
Anquetil, C., Salem, J.-E., Lebrun-Vignes, B., Johnson, D. B., Mammen, A. L., Stenzel, W., Léonard-Louis, S., Benveniste, O., Moslehi, J. J., & Allenbach, Y. (2018) · Circulation · doi:10.1161/circulationaha.118.035898 · Cited by 199
Manohar, S., Kompotiatis, P., Thongprayoon, C., Cheungpasitporn, W., Herrmann, J., & Herrmann, S. M. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy105 · Cited by 193
Ipilimumab in patients with cancer and the management of dermatologic adverse events
Lacouture, M. E., Wolchok, J. D., Yosipovitch, G., Kähler, K. C., Busam, K. J., & Hauschild, A. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.02.035 · Cited by 187
Hematologic Complications of Immune Checkpoint Inhibitors
Davis, E. J., Salem, J.-E., Young, A., Green, J. R., Ferrell, P. B., Ancell, K. K., Lebrun-Vignes, B., Moslehi, J. J., & Johnson, D. B. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0574 · Cited by 177
Immune and molecular correlates in melanoma treated with immune checkpoint blockade
Byrne, E. H., & Fisher, D. E. (2017) · Cancer · doi:10.1002/cncr.30444 · Cited by 172
Kidney injuries related to ipilimumab
Izzedine, H., Gueutin, V., Gharbi, C., Mateus, C., Robert, C., Routier, E., Thomas, M., Baumelou, A., & Rouvier, P. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0092-7 · Cited by 171
Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future
Perazella, M. A., & Shirali, A. C. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018050488 · Cited by 162
Abdel-Rahman, O., Oweira, H., Petrausch, U., Helbling, D., Schmidt, J., Mannhart, M., Mehrabi, A., Schöb, O., & Giryes, A. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1296765 · Cited by 161
Immune Checkpoint Inhibitor Therapy–related Pneumonitis: Patterns and Management
Kalisz, K. R., Ramaiya, N. H., Laukamp, K. R., & Gupta, A. (2019) · RadioGraphics · doi:10.1148/rg.2019190036 · Cited by 159
Kimbara, S., Fujiwara, Y., Iwama, S., Ohashi, K., Kuchiba, A., Arima, H., Yamazaki, N., Kitano, S., Yamamoto, N., & Ohe, Y. (2018) · Cancer Science · doi:10.1111/cas.13800 · Cited by 158
Ma, K., Lu, Y., Jiang, S., Tang, J., Li, X., & Zhang, Y. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01430 · Cited by 152
Wang, W., Lie, P., Guo, M., & He, J. (2017) · International Journal of Cancer · doi:10.1002/ijc.30678 · Cited by 150
Anti–PD-1 Inhibitor–Related Pneumonitis in Non–Small Cell Lung Cancer
Nishino, M., Chambers, E. S., Chong, C. R., Ramaiya, N. H., Gray, S. W., Marcoux, J. P., Hatabu, H., Janne, P. A., Hodi, F. S., & Awad, M. M. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0267 · Cited by 149
Sears, C. R., Peikert, T., Possick, J. D., Naidoo, J., Nishino, M., Patel, S. P., Camus, P., Gaga, M., Garon, E. B., Gould, M. K., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201906-1202st · Cited by 149
Minkis, K., Garden, B. C., Wu, S., Pulitzer, M. P., & Lacouture, M. E. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2012.12.963 · Cited by 146
Ocular and orbital side-effects of checkpoint inhibitors: a review article
Antoun, J., Titah, C., & Cochereau, I. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000296 · Cited by 139
Barroso‐Sousa, R., Ott, P. A., Hodi, F. S., Kaiser, U. B., Tolaney, S. M., & Min, L. (2018) · Cancer · doi:10.1002/cncr.31200 · Cited by 130
Cardiotoxicity from immune checkpoint inhibitors
Michel, L., Rassaf, T., & Totzeck, M. (2019) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2019.100420 · Cited by 130
Jaber, S. H., Cowen, E. W., Haworth, L. R., Booher, S. L., Berman, D. M., Rosenberg, S. A., & Hwang, S. T. (2006) · Archives of Dermatology · doi:10.1001/archderm.142.2.166 · Cited by 127
The gut microbiome and response to immune checkpoint inhibitors: preclinical and clinical strategies
Gong, J., Chehrazi‐Raffle, A., Placencio-Hickok, V., Guan, M., Hendifar, A. E., & Salgia, R. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0225-x · Cited by 116
Neilan, T. G., Rothenberg, M. L., Amiri‐Kordestani, L., Sullivan, R. J., Steingart, R. M., Gregory, W. W., Hariharan, S., Hammad, T. A., Lindenfeld, J. M., Murphy, M. J., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0157 · Cited by 107
Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153
Baban, B., Liu, J. Y., Qin, X., Weintraub, N. L., & Mozaffari, M. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124059 · Cited by 103
Gastrointestinal toxicity of immune checkpoint inhibitors: From mechanisms to management
Samaan, M. A., Pavlidis, P., Papa, S., Powell, N., & Irving, P. M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2018.14 · Cited by 100
Jennings, J. J., Mandaliya, R. H., Nakshabandi, A., & Lewis, J. H. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1574744 · Cited by 98
Cardiac Complications in Immune Checkpoint Inhibition Therapy
Tajiri, K., & Ieda, M. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00003 · Cited by 96
Survival After Fulminant Myocarditis Induced by Immune-Checkpoint Inhibitors
Arangalage, D., Delyon, J., Lermuzeaux, M., Ekpe, K., Éderhy, S., Pagès, C., & Lebbé, C. (2017) · Annals of Internal Medicine · doi:10.7326/l17-0396 · Cited by 87
Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition
Sun, M. M., Levinson, R. D., Filipowicz, A., Anesi, S. D., Kaplan, H. J., Wang, W., Goldstein, D. A., Gangaputra, S. S., Swan, R. T., Sen, H. N., et al. (2019) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2019.1577978 · Cited by 86
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
Naidoo, J., Cappelli, L. C., Forde, P. M., Marrone, K. A., Lipson, E. J., Hammers, H. J., Sharfman, W. H., Le, D. T., Baer, A. N., Shah, A. A., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0390 · Cited by 82
Tajmir-Riahi, A., Bergmann, T., Schmid, M., Agaimy, A., Schuler, G., & Heinzerling, L. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000190 · Cited by 78
McGinnis, G. J., Friedman, D. J., Young, K. H., Torres, E. R. S., Thomas, C. R., Gough, M. J., & Raber, J. (2016) · Oncotarget · doi:10.18632/oncotarget.13551 · Cited by 77
Koda, R., Watanabe, H., Tsuchida, M., Iino, N., Suzuki, K., Hasegawa, G., Imai, N., & Narita, I. (2018) · BMC Nephrology · doi:10.1186/s12882-018-0848-y · Cited by 77
Multifocal radiculoneuropathy during ipilimumab treatment of melanoma
Manousakis, G., Koch, J., Sommerville, R. B., et al. (2013) · Muscle & Nerve · doi:10.1002/mus.23830 · Cited by 76
Ipilimumab: Unleashing the Power of the Immune System Through CTLA-4 Blockade
Boasberg, P. D., Hamid, O., & O'Day, S. J. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.004 · Cited by 75
Checkpoint inhibitor-induced uveitis: a case series
Conrady, C. D., Larochelle, M. B., Pecen, P. E., Palestine, A. G., Shakoor, A., & Singh, A. P. (2017) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-017-3835-2 · Cited by 73
Paueksakon, P., & Fogo, A. B. (2016) · Histopathology · doi:10.1111/his.13064 · Cited by 66
de Malet, A., Antoni, G., Collins, M., Soularue, É., Marthey, L., Vaysse, T., Coutzac, C., Chaput, N., Mateus, C., Robert, C., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.006 · Cited by 59
Vedolizumab: a novel treatment for ipilimumab-induced colitis
Hsieh, A. H., Ferman, M., Brown, M. P., & Andrews, J. M. (2016) · BMJ Case Reports · doi:10.1136/bcr-2016-216641 · Cited by 58
Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities
Pezo, R. C., Wong, M., & Martin, A. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819870911 · Cited by 55
Calvo, R. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00454 · Cited by 54
Hughes, R. C. E., Moore, M. P., Gullam, J., & Rowan, J. (2015) · Diabetes Care · doi:10.2337/dc15-0401 · Cited by 53
Diem, S., Keller, F., Rüesch, R., Maillard, S. A., Speiser, D. E., Dummer, R., Siano, M., Urner-Bloch, U., Goldinger, S. M., & Flatz, L. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000143 · Cited by 52
HBV-related acute hepatitis due to immune checkpoint inhibitors in a patient with malignant melanoma
Köksal, A. Ş., Toka, B., Eminler, A. T., Hacıbekiroğlu, İ., Uslan, M. İ., & Parlak, E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx502 · Cited by 51
Cardiotoxicities associated with immune checkpoint inhibitors
Yang, S., & Asnani, A. H. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.07.002 · Cited by 49
Myasthenia Gravis Induced by Immune Checkpoint Inhibitors
Becquart, O., Lacotte, J., Malissart, P., Nadal, J., Lesage, C., Guillot, B., & Du-Thanh, A. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000278 · Cited by 47
Illouz, F., Briet, C., Cloix, L., Corre, Y. L., Baize, N., Urban, T., Martin, L., & Rodien, P. (2017) · Cancer Medicine · doi:10.1002/cam4.1145 · Cited by 45
How we treat neurological toxicity from immune checkpoint inhibitors
Spain, L. A., Tippu, Z., Larkin, J., Carr, A. S., & Turajlic, S. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000540 · Cited by 45
The Bad and the Good News on Cancer Immunotherapy: Implications for Organ Transplant Recipients
Maggiore, U., & Pascual, J. (2016) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2016.08.002 · Cited by 43
McGinnis, G. J., & Raber, J. (2017) · Immunotherapy · doi:10.2217/imt-2017-0056 · Cited by 43
Side effects of systemic oncological therapies in dermatology
Zimmer, L., Vaübel, J., Livingstone, E., & Schadendorf, D. (2012) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2012.07942.x · Cited by 38
Tucci, M., Passarelli, A. M., Todisco, A., Mannavola, F., Stucci, L. S., D’Oronzo, S., Rossini, M., Taurisano, M., Gesualdo, L., & Silvestris, F. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919875549 · Cited by 34
Deltombe, C., Garandeau, C., Renaudin, K., & Hourmant, M. (2017) · Transplantation · doi:10.1097/tp.0000000000001861 · Cited by 32
Endocrine sequelae of immune checkpoint inhibitors
Ntali, G., Kassi, E. N., & Alevizaki, M. K. (2017) · HORMONES · doi:10.14310/horm.2002.1754 · Cited by 29
Sui, J.-D., Wang, Y., Wan, Y., & Wu, Y. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s167077 · Cited by 27
Inflammatory Arthritis Due to Immune Checkpoint Inhibitors: Challenges in Diagnosis and Treatment
Cappelli, L. C., Naidoo, J., Bingham, C. O., & Shah, A. A. (2016) · Immunotherapy · doi:10.2217/imt-2016-0117 · Cited by 21
Sternschein, R. M., Moll, M. R., Ng, J., & D’Ambrosio, C. M. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201803-0525rr · Cited by 18
Yu, Y., Ruddy, K. J., Tsuji, S., Hong, N., Liu, H., Shah, N. D., & Jiang, G. (2019) · PubMed · Cited by 17
Cited by
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Ye, F., Dewanjee, S., Li, Y., Jha, N. K., Chen, Z.-S., Kumar, A., Vishakha, Behl, T., Jha, S. K., & Tang, H. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01805-y · Cited by 554
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
Johnson, D. B., Manouchehri, A., Haugh, A. M., Quach, H. T., Balko, J. M., Lebrun-Vignes, B., Mammen, A., Moslehi, J. J., & Salem, J.-E. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0617-x · Cited by 366
Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
Cai, X., Zhan, H., Ye, Y., Yang, J., Zhang, M., Li, J., & Zhuang, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.785153 · Cited by 66
Metadata
- Authors
- Choi, J., & Lee, S. Y.
- Venue
- Immune Network
- Publisher
- XMLink
- Published
- 2020
- Volume
- 20
- Issue
- 1
- Pages
- e9-e9
- ISSN
- 1598-2629 (ISSN-L)
- 2092-6685
- OpenAlex
- W3007861202
- Cited by
- 298
- References
- 130
- FWCI
- 11.71
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.